Last fall, Harvard launched the Study of Psychedelics in Society and Culture: an interdisciplinary effort across the Faculty of Arts and Sciences, Harvard Law School, and Harvard Divinity School. At the end of this month, a three-day intensive training camp entitled “Psychedelics Bootcamp 2024” will take place on campus, as part of the work of the Petrie-Flom Center for Health Law and Policy, Biotechnology & Bioethics’s Project on Psychedelics Law and Regulation (POPLAR) , which brings together leading scholars to explore and develop psychedelics law and policy. In recent years, clinical trials for psychedelics such as MDMA and psilocybin have intensified, with companies seeking FDA approval. Randomized clinical trials (RCT) are the gold standard in evidence-based medicine—and usually operate as blind or double-blind studies. These are among the issues that will be explored at Harvard Law School’s psychedelics bootcamp.